Stryker CorporationNYSE: SYK
Health Care · Health Care Equipment
$308.10
+0.05%
Vol: 304K
Research Digest
Tuesday, June 16, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Stryker completed the $435M cash acquisition of Amplitude Vascular Systems on May 7, adding next-generation intravascular lithotripsy technology to its peripheral portfolio.Mixed▶
On May 7, 2026, Stryker completed the acquisition of Amplitude Vascular Systems for approximately $435 million in cash plus up to $400 million in milestone payments, adding a next-generation intravascular lithotripsy platform for complex peripheral arterial disease. Stryker declared a quarterly dividend of $0.88 per share on the same day. The Annual Meeting of Shareholders was held on May 6, with director nominees receiving strong support. Multiple sell-side analysts lowered price targets after the Q1 earnings miss tied to an Iran-linked cyberattack in late March that shut down global manufacturing for nearly three weeks: Baird cut to $385 from $437, Bernstein cut to $410 from $465, and JPMorgan cut to $400 from $445. The consensus from 15 analysts remains Buy with an average target near $397.
May 20Stryker shares move on Bank of America Healthcare Conference participation and post-acquisition momentumMixed▶
Stryker participated in the Bank of America Securities 2026 Global Healthcare Conference on May 13, represented by COO Spencer Stiles and CFO Jason Beach. The company recently closed its $835M acquisition of Amplitude Vascular Systems (May 7) and declared a $0.88 quarterly dividend. SYK shares rose roughly 7.5% over the past week, though they remain down 11.9% YTD after a Q1 dragged by a cyberattack that limited revenue/EPS growth to 1%/14%. Management maintained its 2026 outlook. A DCF view suggests the stock trades at ~16.5% discount to intrinsic value, with analyst PT activity mixed in early May.
May 19Stryker completes $435M Amplitude Vascular Systems acquisition to expand peripheral vascular IVL portfolioMixed▶
Stryker completed the acquisition of Amplitude Vascular Systems (AVS) on May 7, 2026, for approximately $435 million in cash plus up to $400 million in milestones, adding next-generation intravascular lithotripsy technology for complex peripheral arterial disease. The company declared a $0.88 per share quarterly dividend the same day and held its Annual Meeting on May 6 with strong director support. Shares had recovered with a 3.1% surge on May 12 following earlier volatility from Q1 2026 results that missed revenue expectations due to a late-quarter cyberattack distorting sales and margins. Management reaffirmed full-year growth and EPS guidance. Insider activity on May 12 saw CHRO Kathryn Fink sell 8,720 shares for $2.47M. Sentiment is mixed-to-positive as the M&A move offsets lingering cyber-related concerns.
May 18Stryker completes $435M acquisition of Amplitude Vascular Systems for next-gen IVL technology; CHRO sells $2.47M in shares.Mixed▶
Stryker completed its acquisition of Amplitude Vascular Systems (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform for complex peripheral arterial disease, for approximately $435 million in cash plus up to $400 million in milestones. On May 7, the company declared a quarterly dividend of $0.88 per share. The Annual Meeting of Shareholders was held on May 6, with directors receiving strong shareholder support. VP and Chief Human Resources Officer M. Kathryn Fink exercised options to acquire 21,582 shares on May 8 and sold 8,720 shares for $2.47 million on May 11-12. Stryker participated in the Bank of America Securities 2026 Global Healthcare Conference on May 13. Q1 2026 results missed revenue expectations due to a late-quarter cyberattack, but management reaffirmed full-year guidance. SYK shares rose 3.1% to $294.45 on May 12.
May 15Stryker closes Amplitude Vascular acquisition to enter intravascular lithotripsy market and divests US spinal implants business to VB SpineMixed▶
Stryker completed the acquisition of Amplitude Vascular Systems (AVS), gaining a next-generation intravascular lithotripsy (IVL) platform for complex peripheral arterial disease and entering a fast-growing market that has attracted J&J, Boston Scientific and Abbott. The company also completed the sale of its US spinal implants business to Viscogliosi Brothers as part of newly formed VB Spine, sharpening portfolio focus. Q1 2026 net sales rose to $6.02B (from $5.87B), but adjusted EPS missed at $2.60 and statutory EPS missed by 15% at $1.93, driven by a March 2026 cybersecurity incident that disrupted order processing, manufacturing and shipping and raised manufacturing costs. Stryker reaffirmed full-year organic sales and adjusted EPS guidance and raised the quarterly dividend 4.8% to $0.88 (payable July 31). Shares climbed 3.5% on the M&A news and 3.02% on May 13. Risk: residual margin pressure from the cyber incident persists into 2H 2026.
May 14Stryker completes $435M acquisition of Amplitude Vascular Systems while shares rebound after cyberattack disclosureMixed▶
On May 7, 2026, Stryker closed its acquisition of Amplitude Vascular Systems for approximately $435 million in cash plus up to $400 million in milestones, adding next-generation intravascular lithotripsy technology to its peripheral vascular portfolio. Shares rose 3.1% on May 12 to around $294.45, recovering from an early-May selloff triggered by disclosure that an Iran-linked cyberattack in late March had halted global manufacturing for nearly three weeks. Q1 2026 net sales reached $6.02 billion with EPS of $1.93, although gross margin was pressured to 63.3% by the cyber incident. The company also participated in the Bank of America Securities Global Healthcare Conference on May 13. The bear case centers on lingering cyber-related margin pressure and integration risk from the AVS deal.
May 13Stryker shares slump after Argus and Truist cut price targets on cyberattack-driven Q1 miss; completes Amplitude Vascular acquisition.Negative▶
Stryker stock is under heavy pressure (-3% in 24 hours, -9% past week, -15% past month) after a Q1 2026 cyber incident caused a sales and earnings miss (EPS $2.60 vs $2.98 expected; revenue $6B vs $6.34B expected). Argus cut its PT to $350 from $435 while maintaining Buy; Truist lowered PT to $330 from $380; Barclays cut to $394 from $469. Management reaffirmed full-year 2026 guidance, citing 19.5% orthopaedic sales growth and 8.3% international growth as underlying strength. SYK also closed the Amplitude Vascular Systems IVL acquisition on May 7 and sold its U.S. spinal implants business to VB Spine. Risk: ongoing cyber recovery costs and customer-trust impact could pressure margins for additional quarters.
May 12Stryker completes $435M+ Amplitude Vascular Systems acquisition for next-gen IVL technology in peripheral vascular portfolioMixed▶
On May 7, 2026, Stryker completed its acquisition of Amplitude Vascular Systems (AVS), a privately held medtech developing a next-generation intravascular lithotripsy (IVL) platform for complex peripheral arterial disease, for approximately $435M cash plus up to $400M in milestones. The deal expands Stryker's peripheral vascular portfolio. Stryker held its annual meeting on May 6, 2026, where shareholders approved director nominees and a $0.88/share quarterly dividend was declared. Q1 2026 net sales were $6.02B (vs $5.87B prior year), but missed top-line estimates and non-GAAP EPS of $2.60 came in 12.9% below consensus due to a March 11 cyber incident that idled production and pressured gross margin to 63.3%. Stock has rallied with returns of 11.6% (7d), 12.3% (30d), and 16.5% YTD. Stryker presents at BofA Healthcare Conference on May 13.
May 11Stryker completed acquisition of Amplitude Vascular Systems on May 7 and declared an 4.8% dividend hike, but Q1 cyberattack still weighing on shares.Mixed▶
On May 7, 2026, Stryker completed its acquisition of Amplitude Vascular Systems, adding next-generation intravascular lithotripsy (IVL) technology to its peripheral vascular portfolio, and declared a quarterly dividend of $0.88/share (+4.8% YoY) payable July 31. The annual shareholder meeting was held May 6 with all directors re-elected. The company will present at the BofA Global Healthcare Conference on May 13. Q1 2026 revenue of $6.02B (+2.6% YoY) and non-GAAP EPS of $2.60 missed estimates by 12.9%, blamed on an Iran-linked cyberattack in late March that shut global manufacturing for nearly three weeks; shares fell 6.47% to $294.73 on May 1. Risk: ongoing securities investigation tied to the cyber incident and lingering supply chain disruption could pressure Q2 results.
May 8Stryker Q1 revenue and earnings miss 5% and 13% respectively; Iran-linked cyberattack shut manufacturing 3 weeks.Negative▶
Stryker reported Q1 2026 revenue miss of nearly 5% and adjusted earnings miss of nearly 13% on May 1, 2026. An Iran-linked cyberattack (group Handala) hit systems in late March, shutting global manufacturing for nearly three weeks. Stock fell 6.47% to $294.73, touching 52-week low. Despite disruption, company maintained full-year 2026 organic sales growth guidance of 8%-9.5% and adjusted EPS of $14.90-$15.10. Goldman Sachs raised price target to $361 from $357 (May 1), while Truist and Barclays cut targets significantly. Stryker will present at BofA healthcare conference May 13. Recent analyst reactions remain mixed but company confident in 2026 outlook.
May 6Stryker Q1 2026 impacted by cyberattack; Truist lowers price target to $330 from $380.Negative▶
Stryker reported Q1 2026 net sales of $6,020M and net income of $745M, but material cyberattack disrupted production and impacted results. Management reiterated full-year guidance expecting recovery in latter half of 2026. Truist analyst Richard Newitter lowered PT to $330 from $380, keeping Hold rating. Evercore ISI also lowered PT to $365 from $400 maintaining Outperform. Acquisition of Amplitude Vascular Systems announced; NICO Corporation acquisition completed. Calpine spinal implants business sold to VB Spine LLC. Stock at $296.72 with recent gains from Mako SmartRobotics momentum, though cybersecurity incident creates near-term uncertainty.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| ABTABBOTT | $89.68 | +1.14% | +0.9% | 14.6x | 0.62 | $154.4B |
| ISRGINTUITIVE | $419.37 | +0.68% | -5.3% | 35.3x | 1.45 | $147.5B |
| SYKSTRYKER | $308.10 | +0.05% | -1.7% | 18.4x | 0.79 | $118.1B |
| MDTMEDTRONIC | $80.86 | +0.60% | +4.0% | 12.6x | 0.60 | $103.2B |
| BSXBOSTON | $46.69 | -0.16% | -16.4% | 12.6x | 0.56 | $69.5B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.